Illumina Announces HumanOmniExpress+ Custom BeadChip
News Mar 17, 2010
Illumina, Inc. unveiled its new HumanOmniExpress+ Custom BeadChip (OmniExpress+), an enhancement to the recently announced OmniExpress BeadChip that allows for the addition of up to 200,000 custom variants for a total of >900k variants per sample. OmniExpress+ leverages the proven iSelect custom genotyping infrastructure to provide researchers with unlimited flexibility in adding custom content for disease or pathway-specific markers, rare variants from the 1,000 Genomes Project, or panels for fine-mapping onto the industry's most optimal set of SNPs.
"The OmniExpress+ continues Illumina's tradition of supporting semi-custom products, joining the ranks of the 300-Duo+, 550-Quad+ and many others," said Jay Flatley, president and CEO of Illumina. "This addition to our family of third generation arrays leverages our many years of successful custom genotyping projects. The ability to add 3,000 to 200,000 custom variants to the standard OmniExpress provides tremendous flexibility to researchers while accessing the most optimal set of SNPs currently available for genome-wide association studies."
The HumanOmniExpress+ Custom BeadChip is the most versatile custom genotyping product available, with industry-standard data quality ensured by the robust Infinium assay, flexible content design, and high throughput capabilities supported by a multisample BeadChip. Similar to researchers currently using iSelect, OmniExpress+ users will have access to Illumina's assay design software for seamless content design, ensuring the best assay success rate in the industry without the need to pre-screen.
Together with the iScan System and an 8-sample array format, the OmniExpress+ enables the processing of more than 900 samples per week. Like OmniExpress, the foundation of the markers on the OmniExpress+ is a subset of the content powering Illumina's flagship GWAS product, the HumanOmni1-Quad, and includes an optimized set of SNPs chosen from all three phases of the International HapMap Project. Researchers starting with OmniExpress+ can take advantage of future supplemental Omni BeadChips containing new content derived from the 1,000 Genomes Project. As with all Infinium HD products, the OmniExpress BeadChip supports copy number variation (CNV) analyses for disease-association studies and is compatible with Illumina's automation solutions.
Neuroblastoma Biomarker Research Advances TreatmentNews
Neuroblastoma, a childhood cancer, is treatable in less than half of aggressive cases, but new RNA biomarkers may help identify high-risk patients faster and lead to better prognosis.READ MORE
The Exercise Regime of the Future Needs to Check Your GenesNews
Forget protein bars - genes may be central to the exercise regimes of the future, as scientists track down gene changes which occur in response to exercise.READ MORE